Bio-Intelligence Platform
DeepTech Biotech powered by AI trained on real bio-data
Organ Crossing Enhancer
Discovering enhancers that cross the BBB and organ barriers for targeted delivery
CNS & Organ-Specific Theraputics
Applying validated enhancers to accelerate brain and organ-targeted drug development
About Baioflow
Baioflow
Baioflow is a Bio-Intelligence DeepTech biotech company. Its AI engine, BaioAI, is trained on real bio-data to discover organ-crossing enhancers (OCEs) that penetrate the blood-brain barrier (BBB) and other organ barriers, enabling targeted drug delivery.
BaioAI helps accelerate drug development by improving the success rate for CNS and organ-specific therapies.
Our Differentiation
What Makes Baioflow Unique
In drug discovery, biology and AI often speak different languages. Biologists struggle to convert complex experimental data into a format AI can utilize, and AI researchers do not always have access to the experimental insights needed to create meaningful models.
Baioflow bridges this gap.
At Baioflow, we build AI predictive models with preclinical and clinical application value by fusing expertise in biology and AI, and by generating, structuring, and utilizing real biological data. Through this unique method, we discover Organ-Crossing Enhancers (OCEs) and aim to provide them as solutions for next-generation drug delivery.
While most AI-based drug delivery models in the industry rely on theoretical or existing libraries, Baioflow generates purpose-built experimental data to construct our predictive models. This approach is exceptionally rare in the industry, and it is Baioflow's true differentiator.
Learn More about Baioflow
Baioflow's Platform
Baioflow’s Bio-Intelligence Platform: A Complete System from Idea to Therapeutic
Baioflow's Bio-Intelligence platform operates as a single, synergistic closed-loop system, connecting the entire AI drug development process.
Real in vivo data on drug penetration of the blood-brain barrier, generated by BaioLab™, is structured into AI-optimized knowledge by BaioDB™. BaioAI™ learns from this knowledge to discover Organ-Crossing Enhancers (OCEs) that facilitate drug passage across biological barriers. Finally, BaioPartner™ applies this innovative technology to our partners' drug pipelines, advancing them toward real-world therapeutic development.
This integrated process, where each platform creates synergy, maximizes the probability of success in developing targeted therapies for the brain and other specific organs.
BaioLab™: Experimental Discovery
BaioLab™ is our bio-engine that generates the foundational in vivo data for our AI predictions. By accumulating data grounded in experimental fact, we build the essential learning base for our AI models, ensuring their reliability and biological validity.
BaioDB™: From Data to Knowledge
BaioDB™ is the optimal database built to structure biological data from BaioLab™ for AI learning. It ensures data integrity and reproducibility, supporting the development of powerful and accurate AI models.
BaioAI™: From Knowledge to possibilty
BaioAI™ is our AI model that independently learns from and makes predictions based on the refined, real-world data in BaioDB™. It discovers Organ-Crossing Enhancers (OCEs) capable of overcoming barriers like the Blood-Brain Barrier (BBB), opening new possibilities for precision drug delivery.
BaioPartner™: From Possibility to Reality
BaioPartner™ is our collaboration hub, connecting Baioflow's innovative technology with the expertise of our partners. It accelerates the journey from AI-based discovery to real-world therapeutics, delivering new hope to patients faster.
Empowering Innovations through Partnerships
Parterships and Collaborations
BaioPartner™: Accelerating Your Pipeline with Our Bio-Intelligence Platform.
BaioPartner™ is a tailored collaboration program that enables partners to directly leverage Baioflow's Bio-Intelligence platform in their own drug development. Partners can accelerate their internal programs by leveraging the integrated power of Baioflow's technology, from BaioLab™ (generating experimental bio-data) to BaioDB™ (structuring data) and BaioAI™ (providing predictive analysis).
Our partnership model is designed to accelerate the AI-driven drug discovery and unlock new opportunities in challenging fields, such as Central Nervous System (CNS) therapeutics. Partner with Baioflow to deliver faster innovation to more patients.
Our Team
Team of Specialists
“As the head of Baioflow's Bio-Intelligence platform, I am responsible for integrating our four core platforms—BaioLab™, BaioDB™, BaioAI™, and BaioPartner™—into a single, synergistic ecosystem.
Through this integrated platform, my focus is to discover Organ-Crossing Enhancers (OCEs) from real in vivo data and leverage them to realize innovative, targeted drug delivery technologies capable of overcoming biological barriers like the Blood-Brain Barrier (BBB).”
Daehoon Kim
CEO | Biochemistry& Biotech & AI-Driven Drug Discovery Executive
Ph.D., Hokkaido University
“As CTO of Baioflow, I lead the development of our drug delivery platform technology, turning novel ideas into reality. As an expert in Drug Delivery Systems (DDS) and brain-targeting therapeutics, my role is to translate BaioAI™'s predictions into tangible drug delivery technologies.
I lead the research to transform our AI-discovered Organ Crossing Enhancers (OCEs) into functional delivery vehicles that can overcome formidable biological barriers like the Blood Brain Barrier (BBB). I am committed to bridging the gap between AI predictions and real therapeutic value, ensuring our platform makes a tangible impact on the world.”
Hyunsu Min
CTO | Drug Delivery Systems & Brain Target Delivery Expert
Ph.D., Korea University
“I lead the Bio Division at Baioflow, where we drive the creation of the experimental data that builds our BaioLab™ and validates our BaioAI™ engine.
With a background in chemistry and deep expertise in brain-targeted drug delivery, I personally spearhead the design and performance validation of the Organ-Crossing Enhancers (OCEs) uncovered by BaioAI™. I take full ownership of the end-to-end workflow from initial molecular synthesis to final in vivo experiment to ensure that every AI prediction is forged into a proven, reliable technology backed by hard data.”
Yuna Lim
Head of Bio Div. | Chemistry & Brain Target Delivery Expert
ph.D., Aju University